Literature DB >> 20558271

Construction and characterization of an auxotrophic ctxA mutant of O139 Vibrio cholerae.

M Chan1, T Gim Cheong, S Kurunathan, M Chandrika, T Ledon, R Fando, P Lalitha, Z F Zainuddin, M Ravichandran.   

Abstract

Cholera caused by the O139 serogroup still remains a public health concern in certain regions of the world and the existing O1 vaccines do not cross-protect cholera caused by this serogroup. An aminolevulinic acid (ALA) auxotroph vaccine candidate against the O139 serogroup, designated as VCUSM2, was recently developed. It was found to be immunogenic in animal model studies but showed mild reactogenic effects due to the presence of two intact copies of Vibrio cholerae toxin (CTX) genetic element. In the present study we have modified the ctx operon by systematic allelic replacement methodology to produce a mutant strain, designated as VCUSM14. This strain has two copies of chromosomally integrated and mutated ctxA gene, encoding immunogenic but not toxic cholera toxin A subunit (CT-A). The amino acids arginine and glutamic acid at position 7th and 112th, respectively, in CT-A of VCUSM14 were substituted with lysine (R7K) and glutamine (E112Q), respectively. Two copies of the ace and zot genes present in the ctx operon were also deleted. Cholera toxin-ELISA using GM1 ganglioside showed that the both wild type CT and mutated CT were recognized by anti-CT polyclonal antibodies. VCUSM14 produced comparatively less amount of antigenic cholera toxin when compared to the VCUSM2 and Bengal wild type strain. VCUSM14 did not elicit fluid accumulation when inoculated into rabbit ileal loops at doses of 10(6) and 10(8) CFU. The colonization efficiency of VCUSM14 was one log lower than the parent strain, VCUSM2, which can be attributed to the ALA auxotrophy and less invasive properties of VCUSM14. VCUSM14, thus a non-reactogenic auxotrophic vaccine candidate against infection by O139 V. cholerae. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558271     DOI: 10.1016/j.micpath.2010.06.001

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  4 in total

1.  Structural inferences for Cholera toxin mutations in Vibrio cholerae.

Authors:  Gunasagaran Shamini; Manickam Ravichandran; John T Sinnott; Charurut Somboonwit; Harcharan S Sidhu; Paul Shapshak; Pandjassarame Kangueane
Journal:  Bioinformation       Date:  2011-03-02

2.  Construction and evaluation of V. cholerae O139 mutant, VCUSM21P, as a safe live attenuated cholera vaccine.

Authors:  Chandrika Murugaiah; Nik Zuraina Nik Mohd Noor; Shyamoli Mustafa; Ravichandran Manickam; Lalitha Pattabhiraman
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

3.  Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days.

Authors:  Tew Hui Xian; Kurunathan Sinniah; Chan Yean Yean; Venkateskumar Krishnamoorthy; Mohd Baidi Bahari; Manickam Ravichandran; Guruswamy Prabhakaran
Journal:  BMC Immunol       Date:  2020-05-25       Impact factor: 3.615

4.  Live, Genetically Attenuated, Cold-Chain-Free Cholera Vaccine-A Research and Development Journey: Light at the End of a Long Tunnel.

Authors:  Manickam Ravichandran; Hui Xian Tew; Guruswamy Prabhakaran; Subramani Parasuraman; Mohd Nor Norazmi
Journal:  Malays J Med Sci       Date:  2022-04-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.